The endocannabinoid system and liver diseases

Journal of Neuroendocrinology

Volumn 20, Issue SUPPL. 1, 2008, Pages 47-52

  Caraceni, Paolo ^a,b   Domenicali, M ^a,b   Bernardi, M ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ascites; Endogenous cannabinoids; Liver fibrosis, cirrhosis; Non alcoholic fatty liver disease

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CAPSAZEPINE; ENDOCANNABINOID; ISOPRENALINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; N OLEOYLETHANOLAMINE; NITRIC OXIDE; PALMIDROL; RIMONABANT; SR 141716 A; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

CARDIOMYOPATHY; CARDIOTOXICITY; CIRRHOTIC CARDIOMYOPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; HYPERDYNAMIC CIRCULATORY SYNDROME; HYPOVOLEMIC SHOCK; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; SHOCK;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOCANNABINOIDS; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; NEUROSECRETORY SYSTEMS; REPERFUSION INJURY;

EID: 42349090886     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01679.x     Document Type: Conference Paper

References (49)

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
2. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, Hong F, Harvey-White J, Jafri A, Hasko' G, Huffman JW, Gao B, Kunos G, Pacher P. Cannabinoid-2 receptor mediates protection against hepatic ischemia-reperfusion injury. FASEB J 2007; 21: 1781-2000.
3. Bukley NE, Hansson S, Harta G, Mezey E. Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 1998; 82: 1131-1149.
4. ++-dependent and -independent mechanisms. FEBS Lett 1998; 12: 152-156.
5. Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 2006; 29 (Suppl. 3): 58-65.
6. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
7. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16.
8. Kunos G. Understanding metabolic homeostasis and imbalance: What is the role of the endocannabinoid system? Am J Med 2007; 120: S18-S24.
9. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
10. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Peersdorff C, Roque C, Arnone M, Croci T, Soubrie P, Oury-Donat F, Pierre Maffrand J, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/ fa rats. Hepatology 2007; 46: 122-129.
11. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Martinez L, Chavez-Tapia NC, Baptista-González HA, Uribe M. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 2006; 27: 215-219.
12. Mallat A, Lotersztayn S. Endocannabinoids and their receptors in the liver. Am J Physiol 2008; 294: G9-G12.
13. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10: 459-479.
14. Siegmund SV, Shwabe RF. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294: G357-G362.
15. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-676.
16. Julien B, Grenard P, Texeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755.
17. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primery hepatic stellate cells. Hepatology 2005; 41: 1085-1095.
18. Siegmund SV, Qian T, De Minicis S, Harvey-White J, Kunos J, Vinod KY, Hungund B, Schwabe RF. The endocannabinoid 2-arachidonyl glycerol induces death of hepatic stellate cells via mitochondrial oxygen species. FASEB J 2007; 21: 2798-2806.
19. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology 2005; 42: 63-71.
20. Kowalsky HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025-1033.
21. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157.
22. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002; 35: 478-491.
23. Sacerdoti D, Abraham NG, Oyekan AO, Yang L, Gatta A, McGiff JC. Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. J Pharmacol Exp Ther 2004; 308: 636-643.
24. Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology 1993; 18: 621-627.
25. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N, Sanjal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832.
26. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, Martin-Ruiz R, Arroyo V, Rivera F, Rodes J, Jimenez W. A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93.
27. Maccarrone M, Bari M, Battista N, Finazzi-Agrò A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 2002; 1: 53-63.
28. Garcia N Jr, Járai Z, Mirshahi F, Kunos G, Sanyal AJ. Systemic and portal hemodynamic effects of anandamide. Am J Physiol Gastrointest Liver Physiol 2001; 280: G14-G20.
29. Ralevic V, Kendall DA, Randall MD, Smart D. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: Roles in regulation of cardiovascular function. Life Sci 2002; 71: 2577-2594.
30. Domenicali M, Ros J, Fernández-Varo G, Cejudo-Martín P, Crespo M, Morales-Ruiz M, Briones AM, Campistol JM, Arroyo V, Vila E, Rodés J, Jiménez W. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: Role of cannabinoid and vanilloid receptors. Gut 2005; 54: 522-527.
31. Moezi L, Gaskari SA, Liu H, Baik SK, Dehpour AR, Lee SS. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 2006; 149: 898-908.
32. Domenicali M, Caraceni P, Pertosa AM, Giannone F, Principe A, Zambruni A, Trevisani F, Bernadi M. CB1 receptor antagonist SR141716 delays ascitic decompensation in a rat model of liver cirrhosis. Dig Liver Dis 2007; 39: A12.
33. Fernández-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutiérrez ML, Lledó JL, Santander C, Pérez Fernández T, Tomás E, Cacho G, Michael Walker J. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 2004; 24: 477-483.
34. Gaskari SA, Honar H, Lee SS. Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 329-337.
35. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44: 994-1002.
36. Gaskari SE, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomiopathy in bile ductligated rats. Br J Pharmacol 2005; 146: 315-323.
37. Batkai S, Mukhopadhyay P, Harvey-White J, Kekrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007; 293: H1689-H1695.
38. Huguet C, Gavelli A, Chieco A, Bona S, Harb J, Joseph JM, Gramaglia M, Lasserre M. Liver ischemia for hepatic resection: Where is the limit? Surgery 1992; 111: 251-259.
39. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: Risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829-838.
40. Jaeschke H. Mechanisms of liver injury. II. Mechanisms of neutrophilinduced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1083-G1088.
41. Kurabayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Maruyama I, Morishita Y. 2-arachidonylglycerol increases in ischemia-reperfusion injury of rat liver. J Invest Surg 2005; 18: 25-31.
42. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR. 3-(1′1′-Dymethylbutyl)-1-deoxy-delta-8THC and related compounds: Synthesis of selective ligands for CB2 receptor. Bioorg Med Chem 1999; 7: 2905-2914.
43. Colletti LM, Green M. Lung and liver injury following hepatic ischemia/ reperfusion in the rat is increased by exogenous lipopolysaccaride which also increases hepatic TNF production in vivo and in vitro. Shock 2001; 16: 312-319.
44. Marshall JC, Nathens AB. The gut in critical illness: Evidence from human studies. Shock 1996; 6: S10-S16.
45. Tsoulfas G, Takahashi Y, Ganster RW, Yagnick G, Guo Z, Fung JJ, Murase N, Geller DA. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 2002; 74: 7-13.
46. Pillay SP, Moore TD, Lynch SV, Whiting RF, Balderson GA, Strong RW. Endotoxin levels in adult liver donors. Aust NZ J Surg 1994; 64: 615-617.
47. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, Hsu WC, Huang CC, Wang SS, Lo KJ. Endotoxemia in patients with chronic liver diseases: Relation to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22: 165-172.
48. Kojima Y, Suzuki S, Tsuchiya Y, Konno H, Baba S, Nakamura S. Regulation of pro-inflammatory and anti-inflammatory cytokine responses by Kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia. Transpl Int 2003; 16: 231-240.
49. Caraceni P, Pertosa AM, Domenicali M, Cavalieri B, Perrelli MG, Principe A, Cutrin JC, Croa T, Boinardi M. Effect of the cannabinoid CB1 receptor antagonist SR141716 in a rat model of liver inflammation. Hepatology 2004; 40: 698A.